ZMC(SH:600216) Sou Hu Cai Jing·2025-08-13 09:12Group 1 - The core viewpoint of the news highlights the financial performance and stock activity of Zhejiang Medicine Co., Ltd. as of August 13, 2025, showing a stock price increase and significant net profit growth [1] - As of the first quarter of 2025, the company reported total revenue of 2.255 billion yuan, a year-on-year increase of 0.28%, and a net profit attributable to shareholders of 409 million yuan, reflecting a substantial year-on-year growth of 273.08% [1] - The company's liquidity ratios are strong, with a current ratio of 2.854 and a quick ratio of 1.999, indicating good short-term financial health [1] Group 2 - Zhejiang Medicine has made investments in 28 companies and participated in 83 bidding projects, showcasing its active engagement in the market [2] - The company holds 190 trademark registrations and 27 patents, indicating a focus on intellectual property and innovation [2] - Additionally, Zhejiang Medicine has obtained 46 administrative licenses, reflecting its compliance and operational capabilities [2]